Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlaxoSmithKline plc
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
- Other Names / Subsidiaries
- ABR Development
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare